about
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolismEdoxaban, a Novel Oral Factor Xa Inhibitor.Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.Evaluation of Apixaban for the Treatment of Nonvalvular Atrial Fibrillation With Regard to Dosing and Safety in a Community Hospital.Evaluation of the impact of body mass index on warfarin requirements in hospitalized patientsEvaluation of the Safety and Effectiveness of Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation and Coexisting Valvular Heart DiseaseEvaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospitalEvaluation of the effect of prior antiarrhythmic drug use on the success of atrial fibrillation catheter ablationA rare case of a gabapentin-induced cardiomyopathy
P50
Q26746233-E97691D0-DCC8-49BC-AEBE-181A4992BBE3Q38412381-74F61D5B-E01B-4900-A5D3-27F99717255EQ38502450-6C2971F9-A8A9-4B1E-AE0B-2224D1635267Q55346897-9311E167-831B-46AB-97D3-5206060048F9Q64327453-BA5506FA-B8E9-4CEB-9BF1-FF8946908C28Q89643010-DA81672A-F536-4AAA-A55C-F113F6732F92Q90013588-47932579-CDE1-46F8-BBC4-3451BE8DCBEFQ91772630-46DE5980-0979-428F-92E6-AE0E76788036Q92991875-1EAA237F-7FC5-4A71-879B-6BA60881928B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anastasia L Armbruster
@ast
Anastasia L Armbruster
@en
Anastasia L Armbruster
@es
Anastasia L Armbruster
@nl
type
label
Anastasia L Armbruster
@ast
Anastasia L Armbruster
@en
Anastasia L Armbruster
@es
Anastasia L Armbruster
@nl
prefLabel
Anastasia L Armbruster
@ast
Anastasia L Armbruster
@en
Anastasia L Armbruster
@es
Anastasia L Armbruster
@nl
P106
P1153
56405266600
P31
P496
0000-0002-1516-4118